However, the goal of this study was not to study all the outcomes of various subgroups of MDS, including those with SF3B1 mutations, but to demonstrate that there are patients being excluded from the updated WHO classification based on morphologic assessments alone. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.